Point72 Asia (Singapore) Pte. Ltd. Ikena Oncology, Inc. Put Options Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IKNA
# of Institutions
62Shares Held
30.6MCall Options Held
0Put Options Held
0-
Atlas Venture Life Science Advisors, LLC5.02MShares$8.48 Million1.07% of portfolio
-
Bvf Inc San Francisco, CA4.77MShares$8.06 Million0.26% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.09MShares$6.91 Million2.33% of portfolio
-
Orbimed Advisors LLC San Diego, CA3.54MShares$5.98 Million0.14% of portfolio
-
Omega Fund Management, LLC Boston, MA2.25MShares$3.8 Million5.77% of portfolio
About Ikena Oncology, Inc.
- Ticker IKNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,257,500
- Market Cap $61.3M
- Description
- Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...